With facilities in California but headquartered in Pennsylvania, Inovio Pharmaceuticals Inc, (NASDAQ:INO) -- formerly known as Inovio Biomedical Corporation and before that as Genetronics Inc -- is a biomedical company developing drug and gene delivery systems that use electroporation therapy (EPT) to deliver drugs and genes into cells. Stimulating the bodys immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. The firm has developed a synthetic vaccine technology platform that is progressively showing potential to prevent and treat life-altering diseases. Using their synthetic DNA vaccine technology, Inovio is developing a new generation of potential vaccines against infectious disease. This technology enables the design of synthetic vaccines targeting multiple antigens of a disease with the genetic makeup of the antigen based on different strains, to help provide broader preemptive protection against the mutations that will inevitably occur. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.
